loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Caninsulin

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Caninsulin

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    List of centrally authorised products requiring a notification of a change for update of annexes
    List of centrally authorised products requiring a notification of a change for update of annexes

    12 Oct 2018

    // EMA

    https://www.ema.europa.eu/documents/regulatory-procedural-guideline/list-centrally-authorised-products-requiring-notification-change-update-annexes_en-0.pdf

    EMA
    12 Oct 2018
    Share Share
    Insulin NPH, from Indar, is Suspended in Brazil
    Insulin NPH, from Indar, is Suspended in Brazil

    07 Dec 2017

    // ANVISA

    https://www.pharmacompass.com/pdf/news/insulin-nph-from-indar-is-suspended-in-brazil-1512632348.pdf

    ANVISA
    07 Dec 2017
    Share Share